Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Nov;36 Suppl 1(0 1):S3-12.
doi: 10.1016/S0145-2126(12)70003-6.

Can we change the disease biology of multiple myeloma?

Ivan Borrello  1
Affiliations
Review

Can we change the disease biology of multiple myeloma?

Ivan Borrello. Leuk Res. 2012 Nov.

Abstract

Despite improvements in disease management, multiple myeloma (MM) remains incurable. Conventional treatment methods are unsatisfactory, leading to a pattern of regression and remission, and ultimately failure. This pattern suggests that one of the possible strategies for improving outcomes is continuous therapy to maintain suppression of the surviving tumor cells. Optimal management of MM requires potent agents and modalities with direct tumoricidal activity, which can also provide continuous suppression of the residual tumor to prevent disease relapse. Immunomodulatory agents exert immunomodulatory and tumoricidal effects, and cause disruption of stromal cell support from the bone marrow microenvironment. Therefore continuous therapy with immunomodulatory agents may be able to provide both tumor reduction and tumor suppression, enabling physicians to consider the possibility of incorporating continuous therapy into the treatment paradigm of patients with MM.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

Dr. Borrello, MD, obtains research support and serves as a consultant to Celgene Corporation.

Figures

Fig. 1
Fig. 1
Characteristic pattern of remission and relapse following conventional chemotherapy in multiple myeloma. MGUS, monoclonal gammopathy of undetermined significance.
Fig. 2
Fig. 2
B-cell maturation and cell-surface marker expression. * Or other Ig isotype. Ig, immunoglobulin; VDJ, variable diversity, and joining.
Fig. 3
Fig. 3
Multiple myeloma (MM) cell–bone marrow stromal cell (BMSC) interaction. Reproduced with permission from [36] © 2002, Rights Managed by Nature Publishing Group. AKT, protein kinase B; CRE, cyclic AMP-responsive element; ICAM1; intercellular adhesion molecule 1; IGF1, insulin-like growth factor-1; IL-6, interleukin-6; JAK, janus kinase; LFA1, lymphocyte function-associated antigen 1; MAPK, mitogen-activated protein kinase; muc1, mucin 1; NF-κB, nuclear factor κB; PI3K, phosphatidylinositol 3-kinase; SDF-1α, stromal-cell-derived factor-1α; SRE, serum response element; STAT3, signal transducer and activator of transcription 3; TNF-α, tumor necrosis factor-α; VCAM1, vascular cell adhesion molecule 1; VEGF, vascular endothelial growth factor; VLA4, very-late antigen 4.
Fig. 4
Fig. 4
Continuous therapy with IMiD® immunomodulatory agents versus conventional chemotherapy.
See this image and copyright information in PMC

References

    1. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564–9. - PubMed
    1. Kyle RA, Kumar S. The significance of monoclonal gammopathy of undetermined significance. Haematologica. 2009;94(12):1641–4. - PMC - PubMed
    1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860–73. - PubMed
    1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33. - PubMed
    1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–20. - PMC - PubMed

MeSH terms